GlassScriptPhysician profile
Helene E Price
NPI 1003902552
$2,044.35
in general payments reported to CMS, 2019-2025
14 companies · $933 in 2025
The $933 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $33.87 · 2023: $111 · 2024: $645 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $295.17 | 2019-2025 | |
| Galderma Laboratories, L.P. | $254.16 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $213.21 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $201.85 | 2019-2025 | Dupixent |
| Blueprint Medicines Corporation | $182.70 | 2025 | Ayvakit |
| Ucb, INC. | $160.75 | 2024 | Bimzelx |
| Botanix Sb INC | $126.39 | 2025 | Sofdra |
| Incyte Corporation | $124.87 | 2024 | Opzelura |
| Almirall LLC | $118.94 | 2019 | |
| Dermavant Sciences, INC. | $110.50 | 2023 | Vtama |
| Amgen INC. | $100.30 | 2025 | Otezla |
| Astrazeneca Pharmaceuticals LP | $99.60 | 2024 | Saphnelo |
| Axonics, INC. | $33.87 | 2020 | |
| Lilly USA, LLC | $22.04 | 2024 | Olumiant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helene Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.